Press Release

Morgan Lewis Represents Biotech Replimune Group in Public Offering

December 14, 2022

BOSTON, December 14, 2022: Morgan Lewis advised biotechnology company Replimune Group Inc. in its approximately $260 million public offering of 6,810,658 shares of common stock, inclusive of the underwriters’ option to purchase 1,436,172 shares of its common stock, and prefunded warrants to purchase 4.2 million shares of its common stock.

Replimune is a Nasdaq-listed biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform that target cancer by destroying tumor cells and invoking a systemic immune response. 

Morgan Lewis partners Benjamin Stein and Timothy Corbett, of counsel Thurston Hamlette, and associates Saba Habte, Matthew Bugaj, and Davis Truslow represented Replimune.

For more, read Replimune’s announcement.